MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Depreciation & Amortization 2011-2026 | NEOG
Annual Depreciation & Amortization Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 117 M | 88.4 M | 23.7 M | 21 M | 18.4 M | 17.6 M | 17.1 M | 14.7 M | 12.2 M | 10.6 M | 9.18 M | 7.41 M | 6.17 M | 5.33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 5.33 M | 32.5 M |
Quarterly Depreciation & Amortization Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 29.1 M | - | - | - | 29.8 M | - | 23.7 M | 23.7 M | 28.7 M | - | 22.9 M | 22.7 M | 5.73 M | 32.5 M | 2.6 M | 2.4 M | 5.68 M | 11.5 M | - | - | 4.72 M | 9.52 M | - | - | 4.44 M | 8.98 M | 4.44 M | - | 4.27 M | 8.6 M | 4.27 M | - | 3.99 M | 8.27 M | 3.99 M | - | 3.48 M | 7.04 M | 3.48 M | - | 2.7 M | 5.68 M | - | - | 2.52 M | 5.17 M | 2.52 M | - | 2.03 M | 4.17 M | 2.03 M | - | 1.63 M | 3.29 M | 1.63 M | - | 1.38 M | 2.91 M | 1.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.5 M | 1.38 M | 8.77 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
264 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
47 M | $ 8.92 | 0.56 % | $ 594 M | USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 26.01 | 0.68 % | $ 722 M | USA |
 |
DexCom
DXCM
|
252 M | $ 68.2 | 2.8 % | $ 26.6 B | USA |
 |
Charles River Laboratories International
CRL
|
403 M | $ 154.35 | 1.57 % | $ 7.65 B | USA |
 |
CareDx, Inc
CDNA
|
15 M | $ 17.52 | 1.18 % | $ 934 M | USA |
 |
Guardant Health
GH
|
39.7 M | $ 87.53 | 0.4 % | $ 11 B | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | $ 103.87 | 0.01 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M |  China |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 15.53 | 3.88 % | $ 470 M | USA |
|
Biodesix
BDSX
|
5.77 M | $ 17.01 | -1.62 % | $ 2.21 B | USA |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 99.43 | 1.86 % | $ 8.2 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
38.3 K | $ 2.9 | 2.11 % | $ 94.1 K | USA |
 |
IQVIA Holdings
IQV
|
1.14 B | $ 168.32 | 2.14 % | $ 28.9 B | USA |
 |
Danaher Corporation
DHR
|
750 M | $ 194.97 | 1.87 % | $ 139 B | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
354 M | $ 121.42 | 1.79 % | $ 19.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 199.2 | 0.13 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
203 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
321 M | $ 113.43 | 1.43 % | $ 34.5 B | USA |
 |
BioNano Genomics
BNGO
|
14 M | $ 1.12 | 0.66 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
473 K | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.36 | 1.46 % | $ 1.07 B | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 78.46 | -0.05 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
13 M | $ 1.41 | 3.31 % | $ 423 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
1.23 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 452.71 | -0.21 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 215.3 | 1.35 % | $ 25 B |  Schweiz |
 |
Celcuity
CELC
|
130 K | $ 114.14 | -0.66 % | $ 4.5 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.95 | 3.16 % | $ 402 M | USA |
 |
Invitae Corporation
NVTA
|
142 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
16.7 M | $ 199.43 | 0.89 % | $ 19.6 B | USA |
 |
OPKO Health
OPK
|
98.2 M | $ 1.2 | 0.42 % | $ 833 M | USA |